Circulating Tumor Cell-derived Exosome-transmitted Long Non-coding RNA TTN-AS1 Can Promote the Proliferation and Migration of Cholangiocarcinoma Cells

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Apr 18

PMID 38637832

Authors

Xu Zhou

Xiaohan Kong

Jun Lu

Heng Wang

Meng Liu

Shuchao Zhao

Zhaozhi Xia

Qinggong Liu

Hongrui Sun

Xin Gao

Chaoqun Ma

Zheyu Niu

Faji Yang

Xie Song

Hengjun Gao

Shizhe Zhang

Huaqiang Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Exosomes assume a pivotal role as essential mediators of intercellular communication within tumor microenvironments. Within this context, long noncoding RNAs (LncRNAs) have been observed to be preferentially sorted into exosomes, thus exerting regulatory control over the initiation and progression of cancer through diverse mechanisms.

Results: Exosomes were successfully isolated from cholangiocarcinoma (CCA) CTCs organoid and healthy human serum. Notably, the LncRNA titin-antisense RNA1 (TTN-AS1) exhibited a conspicuous up-regulation within CCA CTCs organoid derived exosomes. Furthermore, a significant elevation of TTN-AS1 expression was observed in tumor tissues, as well as in blood and serum exosomes from patients afflicted with CCA. Importantly, this hightened TTN-AS1 expression in serum exosomes of CCA patients manifested a strong correlation with both lymph node metastasis and TNM staging. Remarkably, both CCA CTCs organoid-derived exosomes and CCA cells-derived exosomes featuring pronounced TTN-AS1 expression demonstrated the capability to the proliferation and migratory potential of CCA cells. Validation of these outcomes was conducted in vivo experiments.

Conclusions: In conclusion, our study elucidating that CCA CTCs-derived exosomes possess the capacity to bolster the metastasis tendencies of CCA cells by transporting TTN-AS1. These observations underscore the potential of TTN-AS1 within CTCs-derived exosomes to serve as a promising biomarker for the diagnosis and therapeutic management of CCA.

References

Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A . Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv. 2018; 36(4):1063-1078. PMC: 5971144. DOI: 10.1016/j.biotechadv.2018.03.007. View

Xin Y, He X, Zhao W, Zhan M, Li Y, Xiao J . LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p. Am J Transl Res. 2019; 11(9):6185-6195. PMC: 6789233. View

Morrissey S, Zhang F, Ding C, Montoya-Durango D, Hu X, Yang C . Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021; 33(10):2040-2058.e10. PMC: 8506837. DOI: 10.1016/j.cmet.2021.09.002. View

Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S . Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018; 8(14):3932-3948. PMC: 6071523. DOI: 10.7150/thno.25541. View

Bian B, Li L, Ke X, Chen H, Liu Y, Zheng N . Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing. Front Oncol. 2022; 12:976329. PMC: 9477086. DOI: 10.3389/fonc.2022.976329. View

Li X, Nadauld L, Ootani A, Corney D, Pai R, Gevaert O . Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med. 2014; 20(7):769-77. PMC: 4087144. DOI: 10.1038/nm.3585. View

Wu Y, Hung Y, Chiu N, Lee R, Li C, Chao Y . Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2022; 166:208-218. DOI: 10.1016/j.ejca.2022.01.030. View

Wang H, Liu W, Tian M, Tang Z, Jiang X, Zhou P . Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. Biosci Trends. 2017; 11(4):469-474. DOI: 10.5582/bst.2017.01080. View

Wang Y, Jiang R, Zhao H, Li F, Li Y, Zhu M . TTN-AS1 delivered by gastric cancer cell-derived exosome induces gastric cancer progression through in vivo and in vitro studies. Cell Biol Toxicol. 2022; 39(2):557-571. DOI: 10.1007/s10565-022-09762-w. View

10.

Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klumpen H . Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022; 76(5):1109-1121. DOI: 10.1016/j.jhep.2021.12.010. View

11.

Mondal S, Whiteside T . Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. Melanoma Res. 2021; 31(5):472-475. PMC: 8429197. DOI: 10.1097/CMR.0000000000000762. View

12.

Zhu H, Zhai B, He C, Li Z, Gao H, Niu Z . LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis. Cell Death Dis. 2020; 11(8):637. PMC: 7429853. DOI: 10.1038/s41419-020-02896-x. View

13.

Wu J, Gao W, Tang Q, Yu Y, You W, Wu Z . M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α β Integrin to Tumor Cells. Hepatology. 2020; 73(4):1365-1380. PMC: 8360085. DOI: 10.1002/hep.31432. View

14.

Sapisochin G, Ivanics T, Heimbach J . Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?. Hepatology. 2021; 75(2):455-472. DOI: 10.1002/hep.32258. View

15.

Liu Z, Hu C, Zheng L, Liu J, Li K, Li X . BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. Cell Mol Life Sci. 2022; 79(9):469. PMC: 11071914. DOI: 10.1007/s00018-022-04500-1. View

16.

Cheng J, Meng J, Zhu L, Peng Y . Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications. Mol Cancer. 2020; 19(1):66. PMC: 7098115. DOI: 10.1186/s12943-020-01189-3. View

17.

Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J . Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020; 19(1):15. PMC: 6982393. DOI: 10.1186/s12943-020-1141-9. View

18.

Louis C, Papoutsoglou P, Coulouarn C . Molecular classification of cholangiocarcinoma. Curr Opin Gastroenterol. 2020; 36(2):57-62. DOI: 10.1097/MOG.0000000000000611. View

19.

Javle M, Lowery M, Shroff R, Weiss K, Springfeld C, Borad M . Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2017; 36(3):276-282. PMC: 6075847. DOI: 10.1200/JCO.2017.75.5009. View

20.

Clevers H . Modeling Development and Disease with Organoids. Cell. 2016; 165(7):1586-1597. DOI: 10.1016/j.cell.2016.05.082. View